The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Serious infection following anti–tumor necrosis factor α therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies
Open accessAbstract
Objective: In a recent observational study, we found that the risk of serious infection following anti–tumor necrosis factor α (anti‐TNFα) therapy in patients with rheumatoid arthritis (RA) was not importantly increased compared with the background risk in routinely treated RA patients with similar disease severity. Observational data sets are, however, subject to a number of important biases related to selection factors for the timing of starting and stopping therapy. Infection risk is also likely to vary with duration of therapy. This study was undertaken to examine the influences of these biases and of the method of analysis on the risk of infection. Methods: We compared the risk of serious infection in 8,659 patients treated with anti‐TNFα with that in 2,170 patients treated with traditional disease‐modifying antirheumatic drugs (DMARDs) recruited to the British Society for Rheumatology Biologics Register. We applied a number of statistical models in which we varied the length of the followup period by using different definitions of the date of discontinuation of treatment and different lag periods of risk following drug cessation. Results: When the at‐risk period was defined as “receiving treatment”, the adjusted incidence rate ratio comparing patients receiving anti‐TNFα therapy with patients receiving DMARD therapy was 1.22 (95% confidence interval [95% CI] 0.88–1.69). Limiting followup to the first 90 days, however, revealed an adjusted incidence rate ratio of 4.6 (95% CI 1.8–11.9). Rates of infection were increased in the 90 days immediately following drug discontinuation and beyond, explained by selection factors for drug discontinuation. Conclusion: These findings show that overall, the way in which UK rheumatologists select patients for starting and discontinuing anti‐TNFα therapy explains our previous finding of no increase in risk. However, there may be important increases in true risk, notably early in the course of treatment, that would become more evident depending on the definition of at‐risk period.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Institute for Clinical Excellence
(2001) · Nursing Management · doi:10.7748/nm.8.2.39.s15 · Cited by 3,876
Cohen, S. B., Emery, P., Greenwald, M. W., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., Loveless, J. E., Burmester, G., Cravets, M. W., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22025 · Cited by 1,638
Dixon, W. G., Watson, K., Lunt, M., Hyrich, K. L., Silman, A. J., & Symmons, D. P. M. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21978 · Cited by 751
Self-citationInfections in patients with rheumatoid arthritis treated with biologic agents
Listing, J., Strangfeld, A., Kary, S., Rau, R., von Hinueber, U., Stoyanova‐Scholz, M., Gromnica‐Ihle, E., Antoni, C., Herzer, P., Kekow, J., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21386 · Cited by 681
British Society for Rheumatology Biologics Register
Silman, A. J., Symmons, D. P. M., Scott, D. G. I., & Griffiths, I. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.suppl_2.ii28 · Cited by 248
Self-citationSwedish registers to examine drug safety and clinical issues in RA
Askling, J., Fored, C. M., Geborek, P., Jacobsson, L. T. H., van Vollenhoven, R., Feltelius, N., Lindblad, S., & Klareskog, L. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.045872 · Cited by 157
Kremer, J. M. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.043497 · Cited by 87
The British Society for Rheumatology Biologics Register
Watson, K. D., Symmons, D. P. M., Griffiths, I., & Silman, A. J. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.042499 · Cited by 79
Self-citation
Cited by
Dixon, W. G., Hyrich, K. L., Watson, K. D., Lunt, M., Galloway, J., Ustianowski, A., & Symmons, D. P. M. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.118935 · Cited by 715
Self-citationSingh, J. A., Cameron, C., Noorbaloochi, S., Cullis, T., Tucker, M., Christensen, R., Ghogomu, E. T., Coyle, D., Clifford, T., Tugwell, P., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61704-9 · Cited by 623
Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents
Strangfeld, A. (2009) · JAMA · doi:10.1001/jama.2009.146 · Cited by 542
The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment
Listing, J., Gerhold, K., & Zink, A. (2013) · Rheumatology · doi:10.1093/rheumatology/kes305 · Cited by 541
Nam, J. L., Winthrop, K. L., van Vollenhoven, R. F., Pavelka, K., Valesini, G., Hensor, E. M. A., Worthy, G., Landewé, R., Smolen, J. S., Emery, P., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.126573 · Cited by 406
Metadata
- Authors
- Dixon, W. G., Symmons, D. P. M., Lunt, M., Watson, K. D., Hyrich, K. L., & Silman, A. J.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2007-08-30
- Volume
- 56
- Issue
- 9
- Pages
- 2896-2904
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2120772714
- Cited by
- 307
- References
- 8
- FWCI
- 17.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.